Search Results - drug+delivery+vehicle

73 Results

Sort By:

Extracellular Vesicle mediated nucleic acid treatment in vivo

Value Proposition· Effective: animal studies showed increased survival and decreased tumor burden in liver cancer model.· Fewer side effects: no immunological reactions or off-target effects· Multiple targets: targets the cancer-stroma interactionsUnmet Need· Many current and pipeline cancer therapeutics, including therapeutic...

Published: 3/13/2025 | Inventor(s): Ling Li, Stephen Gould, Florin Selaru

Keywords(s): Drug Delivery Vehicle, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Dextran Hydrogel Scaffolds Enhance Angiogenic Responses and Promote Complete Skin Regeneration During Burn Wound Healing

Unmet Need:Third-degree burns involve damage to both the epidermal and dermal layers and may also entail damage to underlying muscles, bones, and tendons. Such burns heal with thick scars, which result in contractures that distort the surrounding tissue. Deep third-degree burns usually require skin grafting to achieve wound closure, but the cosmetic...

Published: 3/13/2025 | Inventor(s): Guoming Sun, Xianjie Zhang, John Harmon, Sharon Gerecht

Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics, Wound Healing

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Wound Healing, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice

INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...

Published: 3/13/2025 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System

Unmet Need:Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, loss of joint range of motion, and disability. The disease...

Published: 3/13/2025 | Inventor(s): Kevin Yarema, Jennifer Elisseeff, Jeannine Coburn, Udayanath Aich

Keywords(s): Antagonists/Inhibitors, Arthritis, Biologics, Carbohydrates, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Joint Disorders, Novel, Osteoarthritis, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Rheumatology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Rheumatology > Arthritis, Clinical and Disease Specializations > Rheumatology > Osteoarthritis

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 3/13/2025 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof

Unmet NeedMore than 1 million tissue transplantations are performed each year. Organ transplantation therapies are typically combined with immunosuppressive agents to reduce the risk of allograft rejection and to enhance transplant survival. However, current immunosuppressive drugs are administered systemically and have several dose-limiting side effects...

Published: 3/14/2025 | Inventor(s): Giorgio Raimondi, Joel Schneider, Poulami Majumder

Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Inflammatory Disorders, Therapeutic Matter, Therapeutics, Tissue/organ transplant rejection

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases

Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”. The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined with Freshly-extracted Adipose Tissue (F.A.T.) (from...

Published: 3/13/2025 | Inventor(s): Jordan Green, Alfredo Quinones-Hinojosa

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Glioma, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells

Unmet NeedGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases occur when the body’s immune system incorrectly attacks...

Published: 3/14/2025 | Inventor(s): Jordan Green, Jamie Spangler, Stephany Tzeng, Kelly Rhodes, Giorgio Raimondi, Marcos Iglesias Lozano, Jakub Tomala, Derek VanDyke, Randall Meyer

Keywords(s): Autoimmune Diseases, Biologics, Discovery/Research Tools, Disease Indication, Drug Delivery Vehicle, Inflammatory Disorders, Polymers, Recombinant Proteins, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Transplantation, Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Cell Therapies

Novel polyelectrolyte nanoparticle formulation method

JHU Ref #: C13536Value Proposition· Controllable and scalable nanoparticle preparation with narrow and uniform size distribution· Production of condensed and compact polyelectrolyte nanoparticles with improved polymer chain entanglement· Allows for efficient protein encapsulation while retaining their intrinsic physiochemical properties· Nanoparticles...

Published: 3/13/2025 | Inventor(s): Hai-Quan Mao, Jose Santos, Yong Ren, John-Michael Williford

Keywords(s): Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutic Method, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Lipid Nanoparticles as Oral Vehicles of Immunotherapy

Unmet NeedType 1 diabetes (T1D) affects 1.25 million Americans currently and by 2050, this number is expected to reach 5 million. Though a currently untreatable autoimmune disease, one of the more promising approaches has been a costimulatory blockade of malfunctioning immune cells via administration of CTLA4-Ig. However, its efficacy is impeded by...

Published: 3/14/2025 | Inventor(s): Giorgio Raimondi, Julia Patrone, Xiomara Calderon-Colon, Olivia Tiburzi

Keywords(s): Diabetes, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Immunotherapy, Metabolic Disorders, Nanoparticles, Oral Administration, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Clinical and Disease Specializations > Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

1 2 3 4 5 6 7 8